Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 36 of 95, showing 5 Applications out of 471 total, starting on record 176, ending on 180

# Protocol No Study Title Investigator(s) & Site(s)

176.

ECCT/24/05/03   SIBP-MMR-02
    A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age   
Principal Investigator(s)
1. Dr Walter Otieno
2. Dr. Diana Odhiambo
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. Victoria Biomedical Research Institute (Kisumu county)
 
View

177.

ECCT/21/02/03   VAC078
    A Phase III randomized, controlled, multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria.   
Principal Investigator(s)
1. Mainga Patience Mayeso Hamaluba
2. Jean Bosco Ouedraogo
3. Halidou Tinto
4. Alassane Dicko
5. Ally Olotu
Site(s) in Kenya
KEMRI Wellcome Trust Research Programme
 
View

178.

ECCT/20/07/03   STAND
    A Phase III multicenter, randomized, double blind study to assess efficacy and safety of two doses of crizanlizumab verses placebo, with or without hydroxyurea/hydroxycarbamide therapy in adolescent and adult sickle cell disease patients with Vaso-Occlusive Crises (STAND)   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. CREATES Strathmore University (Nairobi City county)
2. Getrudes Childrens Hospital (Nairobi City county)
3. International Cancer Institute (Elgeyo/Marakwet county)
 
View

179.

ECCT/20/10/04   yellow fever vaccine CVIA 079
    A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079.   
Principal Investigator(s)
1. Dr. Deborah Langat
Site(s) in Kenya
KEMRI/KERICHO CLINIC RESEARCH CENTRE
 
View

180.

ECCT/23/02/06   BOHEMIA Safety and Efficacy
    A Phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in Kwale, Kenya.         
Principal Investigator(s)
1. Marta Ferreira Maia
2. Joseph Mwangangi
Site(s) in Kenya
Kwale county, subcounties Lungalunga and Msambweni
 
View